Novel Nano-Drug Delivery System for Brain Tumor Treatment. 2022

Ziyi Qiu, and Zhenhua Yu, and Ting Xu, and Liuyou Wang, and Nanxin Meng, and Huawei Jin, and Bingzhe Xu
School of Biomedical Engineering, Shenzhen Campus of Sun Yat-Sen University, Shenzhen 518107, China.

As the most dangerous tumors, brain tumors are usually treated with surgical removal, radiation therapy, and chemotherapy. However, due to the aggressive growth of gliomas and their resistance to conventional chemoradiotherapy, it is difficult to cure brain tumors by conventional means. In addition, the higher dose requirement of chemotherapeutic drugs caused by the blood-brain barrier (BBB) and the untargeted nature of the drug inevitably leads to low efficacy and systemic toxicity of chemotherapy. In recent years, nanodrug carriers have attracted extensive attention because of their superior drug transport capacity and easy-to-control properties. This review systematically summarizes the major strategies of novel nano-drug delivery systems for the treatment of brain tumors in recent years that cross the BBB and enhance brain targeting, and compares the advantages and disadvantages of several strategies.

UI MeSH Term Description Entries
D001812 Blood-Brain Barrier Specialized non-fenestrated tightly-joined ENDOTHELIAL CELLS with TIGHT JUNCTIONS that form a transport barrier for certain substances between the cerebral capillaries and the BRAIN tissue. Brain-Blood Barrier,Hemato-Encephalic Barrier,Barrier, Blood-Brain,Barrier, Brain-Blood,Barrier, Hemato-Encephalic,Barriers, Blood-Brain,Barriers, Brain-Blood,Barriers, Hemato-Encephalic,Blood Brain Barrier,Blood-Brain Barriers,Brain Blood Barrier,Brain-Blood Barriers,Hemato Encephalic Barrier,Hemato-Encephalic Barriers
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000090783 Nanoparticle Drug Delivery System Engineered NANOPARTICLES with unique physiochemical properties which improve drug BIOAVAILABILITY and site specific drug delivery. NDDSs,Nano Delivery System,Nano Drug Delivery Systems,Nano-Drug Delivery System,Nanoparticle Based Drug Delivery System,Delivery System, Nano,Delivery System, Nano-Drug,Delivery Systems, Nano,Delivery Systems, Nano-Drug,Nano Delivery Systems,Nano Drug Delivery System,System, Nano Delivery,System, Nano-Drug Delivery,Systems, Nano Delivery,Systems, Nano-Drug Delivery
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

Ziyi Qiu, and Zhenhua Yu, and Ting Xu, and Liuyou Wang, and Nanxin Meng, and Huawei Jin, and Bingzhe Xu
January 2024, International journal of nanomedicine,
Ziyi Qiu, and Zhenhua Yu, and Ting Xu, and Liuyou Wang, and Nanxin Meng, and Huawei Jin, and Bingzhe Xu
October 2023, Cancer letters,
Ziyi Qiu, and Zhenhua Yu, and Ting Xu, and Liuyou Wang, and Nanxin Meng, and Huawei Jin, and Bingzhe Xu
January 2022, Frontiers in oncology,
Ziyi Qiu, and Zhenhua Yu, and Ting Xu, and Liuyou Wang, and Nanxin Meng, and Huawei Jin, and Bingzhe Xu
February 2024, Pharmacological research,
Ziyi Qiu, and Zhenhua Yu, and Ting Xu, and Liuyou Wang, and Nanxin Meng, and Huawei Jin, and Bingzhe Xu
June 2012, Expert opinion on drug delivery,
Ziyi Qiu, and Zhenhua Yu, and Ting Xu, and Liuyou Wang, and Nanxin Meng, and Huawei Jin, and Bingzhe Xu
January 2013, Drug delivery,
Ziyi Qiu, and Zhenhua Yu, and Ting Xu, and Liuyou Wang, and Nanxin Meng, and Huawei Jin, and Bingzhe Xu
August 2023, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society,
Ziyi Qiu, and Zhenhua Yu, and Ting Xu, and Liuyou Wang, and Nanxin Meng, and Huawei Jin, and Bingzhe Xu
August 2017, Journal of drug targeting,
Ziyi Qiu, and Zhenhua Yu, and Ting Xu, and Liuyou Wang, and Nanxin Meng, and Huawei Jin, and Bingzhe Xu
February 2018, Anti-cancer agents in medicinal chemistry,
Ziyi Qiu, and Zhenhua Yu, and Ting Xu, and Liuyou Wang, and Nanxin Meng, and Huawei Jin, and Bingzhe Xu
April 2022, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,
Copied contents to your clipboard!